Humanized anti-s100a9 antibody and uses thereof
AssigneeUniversite Laval
InventorsPhilippe TESSIER, Mélanie TARDIF, Traian SULEA
Life of this patent
Estimating the term…
Abstract
It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.
Claims24
An inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2).
6-7. (canceled)
(canceled)
12-14. (canceled)
(canceled)
An antibody comprising an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 2, 21, 22, 23, 25, 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, SEQ ID NO:
- 47, and SEQ ID NO:
- 48.
19-30. (canceled)
Dependencies are inferred from the claim text.